Search Results

There are 205579 results for: content related to: Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas

  1. Clinical application of oxaliplatin in epithelial ovarian cancer

    International Journal of Gynecological Cancer

    Volume 16, Issue 5, September/October 2006, Pages: 1717–1732, S. FU, J.J. KAVANAGH, W. HU and R.C. BAST Jr

    Version of Record online : 17 JUL 2006, DOI: 10.1111/j.1525-1438.2006.00654.x

  2. Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice


    Volume 121, Issue 19, October 1, 2015, Pages: 3428–3434, Anne-Sophie Dussol, Marie-Odile Joly, Cecile Vercherat, Julien Forestier, Valérie Hervieu, Jean-Yves Scoazec, Catherine Lombard-Bohas and Thomas Walter

    Version of Record online : 8 JUN 2015, DOI: 10.1002/cncr.29517

  3. You have free access to this content
    Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site


    Volume 116, Issue 10, 15 May 2010, Pages: 2448–2454, John D. Hainsworth, David R. Spigel, Howard A. Burris III, Dianna Shipley, Cindy Farley, Ines M. Macias-Perez, John Barton and F. Anthony Greco

    Version of Record online : 5 MAR 2010, DOI: 10.1002/cncr.25029

  4. Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma

    British Journal of Haematology

    Volume 174, Issue 6, September 2016, Pages: 899–910, Antònia Obrador-Hevia, Margalida Serra-Sitjar, José Rodríguez, Lamiae Belayachi, Leyre Bento, Marta García-Recio, Jose María Sánchez, Priam Villalonga, Antonio Gutiérrez and Silvia Fernández de Mattos

    Version of Record online : 25 MAY 2016, DOI: 10.1111/bjh.14141

  5. You have free access to this content
    Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer


    Volume 118, Issue 17, 1 September 2012, Pages: 4309–4320, Hanna K. Sanoff, William R. Carpenter, Janet Freburger, Ling Li, Kun Chen, Leah L. Zullig, Richard M. Goldberg, Maria J. Schymura and Deborah Schrag

    Version of Record online : 31 JAN 2012, DOI: 10.1002/cncr.27422

  6. A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors

    Pediatric Blood & Cancer

    Volume 60, Issue 2, February 2013, Pages: 230–236, Margaret E. Macy, Tracey Duncan, James Whitlock, Stephen P. Hunger, Jessica Boklan, Aru Narendran, Cynthia Herzog, Robert J. Arceci, Rochelle Bagatell, Tanya Trippett, Uwe Christians, Katherine Rolla, S. Percy Ivy, Lia Gore and on behalf of the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC)

    Version of Record online : 28 SEP 2012, DOI: 10.1002/pbc.24278

  7. You have free access to this content
    Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients


    Volume 118, Issue 12, 15 June 2012, Pages: 3173–3181, C. Daniel Mullins, Fei-Yuan Hsiao, Eberechukwu Onukwugha, Naimish B. Pandya and Nader Hanna

    Version of Record online : 21 OCT 2011, DOI: 10.1002/cncr.26613

  8. Effects of oxaliplatin and oleic acid Gc-protein-derived macrophage-activating factor on murine and human microglia

    Journal of Neuroscience Research

    Volume 93, Issue 9, September 2015, Pages: 1364–1377, Jacopo J.V. Branca, Gabriele Morucci, Francesca Malentacchi, Stefania Gelmini, Marco Ruggiero and Stefania Pacini

    Version of Record online : 18 MAR 2015, DOI: 10.1002/jnr.23588

  9. Systemic Treatment of Hepatobiliary Tumors

    Malignant Liver Tumors: Current and Emerging Therapies, Third Edition

    Panagiotis Samaras, Michael A. Morse, Bernhard C. Pestalozzi, Pages: 107–121, 2009

    Published Online : 9 DEC 2009, DOI: 10.1002/9781444317053.ch10

  10. You have free access to this content
    PKC/MEK inhibitors suppress oxaliplatin-induced neuropathy and potentiate the antitumor effects

    International Journal of Cancer

    Volume 137, Issue 1, 1 July 2015, Pages: 243–250, Masanobu Tsubaki, Tomoya Takeda, Tadahumi Tani, Hirotaka Shimaoka, Naohiro Suzuyama, Kotaro Sakamoto, Arisa Fujita, Naoki Ogawa, Tatsuki Itoh, Motohiro Imano, Yoshinori Funakami, Seiji Ichida, Takao Satou and Shozo Nishida

    Version of Record online : 8 DEC 2014, DOI: 10.1002/ijc.29367

  11. You have free access to this content
    Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults


    Volume 118, Issue 11, 1 June 2012, Pages: 2925–2934, Christina D. Mack, William Carpenter, Anne-Marie Meyer, Hanna Sanoff and Til Stürmer

    Version of Record online : 9 NOV 2011, DOI: 10.1002/cncr.26622

  12. The role of oxaliplatin in the management of upper gastrointestinal tract malignancies

    Colorectal Disease

    Volume 5, Issue s3, November 2003, Pages: 36–44, W. Scheithauer and E. Van Cutsem

    Version of Record online : 30 OCT 2003, DOI: 10.1046/j.1463-1318.5.s3.5.x

  13. You have full text access to this OnlineOpen article
    Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review

    Cancer Medicine

    Volume 3, Issue 6, December 2014, Pages: 1502–1511, Frédéric Fiteni, Thierry Nguyen, Dewi Vernerey, Marie-Justine Paillard, Stefano Kim, Martin Demarchi, Francine Fein, Christophe Borg, Franck Bonnetain and Xavier Pivot

    Version of Record online : 11 AUG 2014, DOI: 10.1002/cam4.299

  14. Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells

    Journal of Cellular Biochemistry

    Volume 105, Issue 4, 1 November 2008, Pages: 971–979, Shin Kim, Tae-Jin Lee, Jong-Wook Park and Taeg Kyu Kwon

    Version of Record online : 2 SEP 2008, DOI: 10.1002/jcb.21905

  15. You have full text access to this Open Access content
    Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines

    Cancer Science

    Volume 102, Issue 2, February 2011, Pages: 382–386, Eiji Kashiwagi, Hiroto Izumi, Yoshihiro Yasuniwa, Ryoko Baba, Yoshiaki Doi, Akihiko Kidani, Tokuzo Arao, Kazuto Nishio, Seiji Naito and Kimitoshi Kohno

    Version of Record online : 19 NOV 2010, DOI: 10.1111/j.1349-7006.2010.01784.x

  16. You have free access to this content
    Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules


    Volume 98, Issue 12, 15 December 2003, Pages: 2664–2670, Julien Taïeb, Luminita Bonyhay, Lamia Golli, Michel Ducreux, Emmanuel Boleslawski, Jean-Marie Tigaud, Thierry de Baere, Touraj Mansourbakht, Marie Anna Delgado, Laureut Hannoun, Thierry Poynard and Valerie Boige

    Version of Record online : 10 NOV 2003, DOI: 10.1002/cncr.11869

  17. You have free access to this content
    Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma

    FEBS Letters

    Volume 529, Issue 2-3, October 09, 2002, Pages: 232–236, Isabelle Gourdier, Maguy Del Rio, Laure Crabbé, Laurent Candeil, Virginie Copois, Marc Ychou, Charles Auffray, Pierre Martineau, Nadir Mechti, Yves Pommier and Bernard Pau

    Version of Record online : 11 SEP 2002, DOI: 10.1016/S0014-5793(02)03347-1

  18. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry

    Asia-Pacific Journal of Clinical Oncology

    Volume 11, Issue 4, December 2015, Pages: 334–342, Young Suk Park, Jiafu Ji, John Raymond Zalcberg, Mostafa El-Serafi, Antonio Buzaid and Marwan Ghosn

    Version of Record online : 15 OCT 2015, DOI: 10.1111/ajco.12409

  19. Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo

    Clinical and Experimental Pharmacology and Physiology

    Volume 40, Issue 6, June 2013, Pages: 371–378, Virginia Ip, Johnson J Liu and Mark J McKeage

    Version of Record online : 28 MAY 2013, DOI: 10.1111/1440-1681.12088

  20. Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization


    Volume 70, Issue 7, July 2015, Pages: 784–794, E. Alvarez-Cuesta, R. Madrigal-Burgaleta, D. Angel-Pereira, A. Ureña-Tavera, M. Zamora-Verduga, P. Lopez-Gonzalez and M. P. Berges-Gimeno

    Version of Record online : 24 APR 2015, DOI: 10.1111/all.12620